Real world data of ixazomib in combination with lenalidomide and dexamethasome

Rakesh Popat

Ixazomib is a novel oral proteosome inhibitor approved in combination with lenalidomide and dexamethasome for the treatment of relapsed/refractory multiple myeloma. Here, Rakesh Popat, MD, PhD from the University College London, London, UK talks about the real world data presented at European Hematology Association (EHA) 2017 meeting.

Share this video